{"name":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","slug":"chengdu-kanghong-pharmaceutical-group-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Aripiprazole tablets","genericName":"Aripiprazole tablets","slug":"aripiprazole-tablets","indication":"Schizophrenia","status":"phase_3"},{"name":"Hydrochloride Carliprazine capsules","genericName":"Hydrochloride Carliprazine capsules","slug":"hydrochloride-carliprazine-capsules","indication":"Schizophrenia","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Bosiqing","genericName":"Bosiqing","slug":"bosiqing","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Aripiprazole tablets","genericName":"Aripiprazole tablets","slug":"aripiprazole-tablets","phase":"phase_3","mechanism":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors, which stabilizes dopamine and serotonin neurotransmission in the brain.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)","Major depressive disorder (adjunctive treatment)","Autism spectrum disorder (irritability)"],"catalyst":""},{"name":"Bosiqing","genericName":"Bosiqing","slug":"bosiqing","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hydrochloride Carliprazine capsules","genericName":"Hydrochloride Carliprazine capsules","slug":"hydrochloride-carliprazine-capsules","phase":"phase_3","mechanism":"Carliprazine is an atypical antipsychotic that acts as a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A receptor partial agonist.","indications":["Schizophrenia","Bipolar disorder (acute mania/mixed episodes)","Major depressive disorder (adjunctive treatment)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPZldyVnNIcjJZZ3lXME55d1luQ0NIam5mSmJsMi1ZRlcwc3ZJazlzU0FfU3BhRkNxV3VlTU95ZUlBckhaYUNQeGVDUVJhRTFFZVI3aFkxeDBpNVhYcDEwZU1BZFoxVTBCdXd4b2VtUDd1dUFpVmp5VEdieG9aSE5wVjdEWUNCZXJndk15WXFIYXdTUzZpaXQxNkhad1FnQXlOZGc?oc=5","date":"2026-02-19","type":"earnings","source":"Statista","summary":"Major pharmaceutical companies by profit growth - Statista","headline":"Major pharmaceutical companies by profit growth","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-26","type":"pipeline","source":"GlobeNewswire","summary":"Retinitis Pigmentosa Research Report 2025: $25+ Bn Market - GlobeNewswire","headline":"Retinitis Pigmentosa Research Report 2025: $25+ Bn Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOSTBTR2Uta25lV3JDN09ySjVNQlgtSG94Z1hkclBXcmc3cm9RcDRxN1dnSHZxYnNXUzdydTU2aEhsWk1UaTdkRVpPRS1iV080T3pRSGxNcXMyV2dhRHBfdUt4dm5WOUVVSmI2Uml2UWljd3VTT0UtVmROc2pGWTRDblVDQ2dZYUljNkhsb1Z4ZzB5OWlXNGR6QnBkUF9FOFc3M3BBSjdGanpFSDRUa1dVcUpGY3BTQlhqUVlSQklnRHNZZ0FPd0VjaGlSc21uYlVlVlZpbnJxM2U?oc=5","date":"2025-05-07","type":"pipeline","source":"UMass Chan Medical School","summary":"Origen Biotechnology funds research at UMass Chan to advance gene therapy technology - UMass Chan Medical School","headline":"Origen Biotechnology funds research at UMass Chan to advance gene therapy technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPZnNiRk9QWjh0NlAzNkVOSFZvaENDbjlRVGxoUGUtU3BIM3FuRkNIUGo5WGlhLWFVcTRRd3h0NlFqc3pkUmZLbG1xRE5aZFcxaWFVbTA1SWFsZUhCYnVjREw0MUItS0JEWjF0bXZWSi1TbFltd01xb09kMkdSV2V3Ty12QlZibVdjUmQtVTBPMEdTc0t2Vlptc0F3X2wyblppNzhSSnZod2F3UmJiRGxYN0tSOWpQM3M3WXB0dUs0c1JQQ0k2V2VYbVZRYVh2MlZ5ZUFHTm1R?oc=5","date":"2024-09-27","type":"pipeline","source":"PR Newswire","summary":"AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR | MarketsandMarkets™ - PR Newswire","headline":"AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR | MarketsandMarkets™","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBQRXFjcWZiX2VUV0ZNNmpSbFRmaFRxamVQemFTUE9xVHdUYzZPOXFiNHJhdkxDNU5KeFBZVWs0RzZrbTBNekFHVG56NmExVWpGMTB4MFVma3ByWFpyVFRV?oc=5","date":"2024-05-06","type":"pipeline","source":"Nature","summary":"An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species - Nature","headline":"An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQS21RcjlrX20tSW4yRWlIbXhNQ3N6Wl9nRWpOa21QTlhrQXFvOUtuWERwcjZtLUYzY1NBTk11SFZnTVVBMGxVQTkyZ0NXbnRMaVNPbVVYRmFPZVZmcl9XdmhJUzUydWZrRWx3NjVIX0hlYlVkU3g5N05MU1FiekR2N2JYVW5TaWh3by02elAtY1RFM2VkandVWXJXWkVUSUNBUy1mOXdaeTZkMk9OVGNLX0tZRkZmcVlROGpuV0NPWWpyNjE2aVZ5RjhGZXVtNlJ1Tm10M2paanZiUHlDVHFEMThnWTlQZFlK?oc=5","date":"2021-05-05","type":"pipeline","source":"GlobeNewswire","summary":"Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031 - GlobeNewswire","headline":"Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOaUxhR0MyREJLdTBxNmhTMTB4ekpXS3JEazV2Q2JpRmlfLU81UjU4bjNwUmN3OEZtRUtFT0NkNlRLNUdadDJHV1FTeGFqNFdZLXdiUVNkNk9zWDU2TFRmZ3FOblNtOXNBcS1DMzB3LWJrM3MtMG9BX3Z1RmZaSmdJdGhrb0gxaEIxRHE0dDVn?oc=5","date":"2020-12-01","type":"pipeline","source":"Quiver Quantitative","summary":"Dimensional Emerging Core Equity Market ETF Holdings - Quiver Quantitative","headline":"Dimensional Emerging Core Equity Market ETF Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOcEcxLW9fQU5DNjNLbFpFX2djbkZaTnQwMU1SS2tua0g3MFpkdmIzZnVOM3VKb2xTZlBXd3Vyd1I0NkMtUVNLYmN3aUxpQ1VJbS1sN2JfX0JiZllnMEUtakJydWNWNTdZSGVCcV9tUVdGV2hNSmFLelpuWTVNS01kakFoRTVld201S19qZ3FxTGo3bGZmekdObWg4X2FucUR5TjQ3d0wxc1BycWVlM3E2T050MDk?oc=5","date":"2019-01-02","type":"pipeline","source":"Bloomberg.com","summary":"Even After a $46 Billion Plunge, China's Drugmakers May Have a Long Way to Fall - Bloomberg.com","headline":"Even After a $46 Billion Plunge, China's Drugmakers May Have a Long Way to Fall","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1fTzVVMXFoaWFuQ3ZuUlhpc3RMSHhVOXJRRTU2bVMyMm5TOXpOOGlMMklGMWxmU1Z4MnB3NXNtdUVncWJEVFhUaHYxRy1naW9RNmE4TmI3VVo2TFUxZWFQOWNqdnRwZ01aSDVTOG5rQ2x5ckI4MFE0?oc=5","date":"2018-09-27","type":"pipeline","source":"CTech","summary":"Chengdu Kanghong Pharma Solidifies Ownership of Israeli Medical Device Company - CTech","headline":"Chengdu Kanghong Pharma Solidifies Ownership of Israeli Medical Device Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZUdiMUI2RERBcXVHOGg4c1g3Y0Z2QzhwcTF4NTBaazBsOEE0MXdPTl93NEctQkE4Q1QzQTV4RFBrU0RhVXFmeUZnV3ZUT3l3Nmc3MzFraVRDT2Fvdkp3M3cxXy0yUmFhd3NnWm5uZ2pSZ3BqampMcGh0czl2ZWNFemJJYkZTcXdpd01PcS10NW1GSTBiYm5wMWhxc2xLTUlTSGkwT09lQVB4aFJvT0JfdVgzdXRnWnd6bnR3?oc=5","date":"2013-05-13","type":"regulatory","source":"Asian Scientist Magazine","summary":"Sagent Pharma To Acquire Remaining Interest In Chengdu Kanghong Pharma - Asian Scientist Magazine","headline":"Sagent Pharma To Acquire Remaining Interest In Chengdu Kanghong Pharma","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}